Cargando…

Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy

Treatment with glucocorticoid (GC) is the preferred therapy for polymyalgia rheumatica (PMR), but some patients show poor responses to the initial GC regimen or experience flares on GC tapering. Alternative therapies for patients with GC resistance have not yet been established. To evaluate pretreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Shunsuke, Koga, Yukinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844628/
https://www.ncbi.nlm.nih.gov/pubmed/24803231
http://dx.doi.org/10.1007/s10067-014-2650-y
_version_ 1782428807022510080
author Mori, Shunsuke
Koga, Yukinori
author_facet Mori, Shunsuke
Koga, Yukinori
author_sort Mori, Shunsuke
collection PubMed
description Treatment with glucocorticoid (GC) is the preferred therapy for polymyalgia rheumatica (PMR), but some patients show poor responses to the initial GC regimen or experience flares on GC tapering. Alternative therapies for patients with GC resistance have not yet been established. To evaluate pretreatment characteristics and therapeutic outcomes of GC-resistant PMR, we followed all patients who had been diagnosed with PMR between October 2007 and February 2013, according to our standardized protocol. GC-resistant patients were defined as those who had responded poorly to the initial GC regimen (15 mg/day of prednisolone) or those who had responded to the initial regimen but had experienced a flare upon GC tapering to 5 mg/day of the maintenance dose or within the first 6 months of maintenance therapy. Out of 23 patients, nine were found to be GC-resistant cases and the others were GC responders. Baseline values of PMR activity score and its components, especially the ability to elevate the upper limbs (EUL), were significantly higher in GC-resistant patients compared with GC responders. The additional use of methotrexate (MTX, five cases), salazosulfapyridine (one case), and tocilizumab (TCZ, three cases) was effective for GC-resistant patients, although 13 to 39 weeks were required for the achievement of remission. We report the three GC-resistant cases in which TCZ was added to GC therapy with or without MTX. We also review the medical literature on the use of TCZ as of January 31, 2014 and discuss the utility of TCZ in the treatment of GC-resistant PMR.
format Online
Article
Text
id pubmed-4844628
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-48446282016-05-21 Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy Mori, Shunsuke Koga, Yukinori Clin Rheumatol Case Based Review Treatment with glucocorticoid (GC) is the preferred therapy for polymyalgia rheumatica (PMR), but some patients show poor responses to the initial GC regimen or experience flares on GC tapering. Alternative therapies for patients with GC resistance have not yet been established. To evaluate pretreatment characteristics and therapeutic outcomes of GC-resistant PMR, we followed all patients who had been diagnosed with PMR between October 2007 and February 2013, according to our standardized protocol. GC-resistant patients were defined as those who had responded poorly to the initial GC regimen (15 mg/day of prednisolone) or those who had responded to the initial regimen but had experienced a flare upon GC tapering to 5 mg/day of the maintenance dose or within the first 6 months of maintenance therapy. Out of 23 patients, nine were found to be GC-resistant cases and the others were GC responders. Baseline values of PMR activity score and its components, especially the ability to elevate the upper limbs (EUL), were significantly higher in GC-resistant patients compared with GC responders. The additional use of methotrexate (MTX, five cases), salazosulfapyridine (one case), and tocilizumab (TCZ, three cases) was effective for GC-resistant patients, although 13 to 39 weeks were required for the achievement of remission. We report the three GC-resistant cases in which TCZ was added to GC therapy with or without MTX. We also review the medical literature on the use of TCZ as of January 31, 2014 and discuss the utility of TCZ in the treatment of GC-resistant PMR. Springer London 2014-05-08 2016 /pmc/articles/PMC4844628/ /pubmed/24803231 http://dx.doi.org/10.1007/s10067-014-2650-y Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Case Based Review
Mori, Shunsuke
Koga, Yukinori
Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
title Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
title_full Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
title_fullStr Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
title_full_unstemmed Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
title_short Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
title_sort glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
topic Case Based Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844628/
https://www.ncbi.nlm.nih.gov/pubmed/24803231
http://dx.doi.org/10.1007/s10067-014-2650-y
work_keys_str_mv AT morishunsuke glucocorticoidresistantpolymyalgiarheumaticapretreatmentcharacteristicsandtocilizumabtherapy
AT kogayukinori glucocorticoidresistantpolymyalgiarheumaticapretreatmentcharacteristicsandtocilizumabtherapy